Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada

15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...

Read more →

Obscure model puts a price on good health—and drives down drug costs

4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...

Read more →

Report clearly demonstrates the value of vaccines

1 November 2019 - Medicines Australia welcomes today’s report from the Australian Institute of Health and Welfare which verifies the ...

Read more →

Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines

17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who ...

Read more →

Some say a non-profit research group unfairly influences drug prices

16 October 2019 - Have you ever wondered how pharmaceutical companies decide whether that pill you take costs $3 or ...

Read more →

Accounting for hope: using ‘mean survival gain’ to price new cancer drugs

14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...

Read more →

'Veiled in secrecy': call for surgeons to disclose complications rates

14 October 2019 - Surgeons are being urged to disclose their rates of surgical complications to prove they're worth the ...

Read more →

PhRMA Foundation partners with National Health Council to host first of its kind conference on new approaches to value assessment

10 October 2019 - The PhRMA Foundation and the National Health Council will host The Next Generation of Value Assessment: ...

Read more →

As value assessment frameworks evolve, are they finally ready for prime time?

9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...

Read more →

Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States

5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...

Read more →

What is the value of market-wide health care price transparency?

5 September 2019 - A primary driver of high spending in the US health care system, relative to other countries, ...

Read more →

ICER's value framework and patient feedback: Q&A with Steve Pearson

15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...

Read more →

Costing methods applied to cancer

8 August 2019 - Health care is vital in improving quality and length of life.  ...

Read more →

A non-inferiority framework for cost-effectiveness analysis

24 July 2019 - Traditional decision rules have limitations when a new technology is less effective and less costly than a ...

Read more →

Should national pharmacare apply a value based insurance design?

22 July 2019 - The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, ...

Read more →